CCT241161

WARNING: This product is for research use only, not for human or veterinary use.

Description:CCT241161 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. CCT241161 blocked growth of BRAF-mutant and NRAS-mutant melanoma cells, inhibiting MEK–ERK, in vitro and in vivo. CCT241161 also prevented growth of xenografts derived from patient tumours with acquired or intrinsic resistance to BRAF and MEK inhibitors. BRAF and MEK inhibitors are effective in BRAF mutant melanoma, but most patients eventually relapse with acquired resistance, and others present intrinsic resistance to these drugs.

Price and Availability

CCT241161,is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 406644Name: CCT241161CAS#: 1163719-91-2Chemical Formula: C28H27N7O3SExact Mass: 541.18961Molecular Weight: 541.62Elemental Analysis: C, 62.09; H, 5.02; N, 18.10; O, 8.86; S, 5.92

Synonym:CCT241161; CCT-241161; CCT 241161.

IUPAC/Chemical Name:1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-(methylthio)-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea

InChi Key:DPMYVVGAYAPQNS-UHFFFAOYSA-N

InChi Code:InChI=1S/C28H27N7O3S/c1-28(2,3)22-15-23(35(34-22)17-8-6-5-7-9-17)32-27(37)31-19-11-10-18(14-21(19)39-4)38-20-12-13-29-26-25(20)30-16-24(36)33-26/h5-16H,1-4H3,(H,29,33,36)(H2,31,32,37)

SMILES Code:CSC1=CC(OC2=C3C(NC(C=N3)=O)=NC=C2)=CC=C1NC(NC4=CC(C(C)(C)C)=NN4C5=CC=CC=C5)=O

Technical Data

Additional Information

References

1: Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D,Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D,McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, CarragherN, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, LoriganP, MaraisR, Springer C. Paradox-breaking RAF inhibitors that also target SRC areeffective in drug-resistant BRAF mutant melanoma. Cancer Cell. 2015 Jan12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11. PubMed PMID:25500121; PubMed Central PMCID: PMC4297292.